Hedge funds cut NFLX, keep big bets on MSFT, AMZN, add NVDA
Verastem, Inc. (NASDAQ:VSTM) President and CEO Dan Paterson, disposed of 335 shares of common stock on June 16, 2025, at a price of $5.65, for a total transaction value of $1892. The transaction occurs as the stock shows mixed performance, down 7% in the past week but up nearly 60% over the last year. According to InvestingPro analysis, the $283.54M market cap company currently trades near its Fair Value. According to a Form 4 filing with the Securities and Exchange Commission, the shares were sold to satisfy statutory withholding requirements in connection with the vesting of restricted stock units. InvestingPro data reveals the company holds more cash than debt on its balance sheet, though it’s currently not profitable. Following the transaction, Paterson directly owns 461,647 shares of Verastem. For deeper insights into VSTM’s financial health and 8 additional ProTips, consider exploring the comprehensive Pro Research Report available on InvestingPro.
In other recent news, Verastem Oncology has reported promising results from its Phase 1/2 trial of the drug GFH375, also known as VS-7375, for treating certain cancers. The trial, conducted in China with partner GenFleet Therapeutics, showed a 52% overall response rate in pancreatic ductal adenocarcinoma (PDAC) patients and 42% in non-small cell lung cancer (NSCLC) patients. Verastem is preparing to launch a U.S.-based Phase 1/2a study of VS-7375, focusing on advanced KRAS G12D mutant solid tumors. Additionally, Verastem’s RAMP 205 Phase 1/2 trial reported an 83% overall response rate in treating metastatic PDAC, with plans to commence a Phase 3 study in 2026. Jefferies has raised its price target for Verastem to $19, following early FDA approval for its avutometinib and defactinib combination therapy for recurrent KRAS mutant low-grade serous ovarian cancer. Mizuho (NYSE:MFG) maintains an Outperform rating with an $8 target, citing confidence in Verastem’s financial standing and upcoming data presentations. Cantor Fitzgerald also reaffirmed its Overweight rating, reflecting confidence in the company’s research and development initiatives. These developments highlight Verastem’s active engagement in advancing cancer therapies and its strategic focus on RAS/MAPK pathway-driven cancers.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.